Journal of Integrative Oncology

Memorial Sloan-Kettering Cancer Center, New York, USA

Publications

• Review Article   
  Immune Response Impact of Childhood Acute Myeloid Leukemia
  Author(s): Ludmila Cavalcante*
  
  Constant myeloid leukaemia (CML) is characterised by a BCR-ABL1 combination quality of proportional chromosomal mobility, which indicates the presence of a clonal myeloproliferative threat. CML is a rare disease that affects children and teens, with a predicted annual frequency of 2.5 cases per million in children and young adults. It accounts for 2-3% of all instances of childhood leukaemia and 9% of cases of leukaemia in teenagers between the ages of 15 and 19. Tyrosine kinase inhibitor (TKI) therapy is the standard of care for individuals with CML, and it is only possible to stop TKI therapy in a small percentage of patients. Patients with CML now have significantly more endurance thanks to the introduction of TKIs. Long-term TKI treatment is required for CML children, and routine immunizations have been hindered by the lack of knowledge regarding TKI safety.. Read More»
  DOI: 10.37421/2329-6771.2022.11.392

  Abstract HTML PDF